6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS

Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS

Quick Clinical Summary: After the acute CRS/ICANS window, surveillance continues for IEC-HS, prolonged or biphasic cytopenias, infection, immune deficits, organ effects, treatment failure or relapse, and subsequent malignancy. IEC-HS is diagnosed from a constellation and treated by severity under specialist protocols; ferritin alone is insufficient. Growth factor, antimicrobial prophylaxis, and immunoglobulin replacement are individualized to timing, counts, immune recovery, infections, and the product/center plan.

---

1. Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS)

ASTCT defines IEC-HS as a pathologic hyperinflammatory syndrome attributable to immune-effector-cell therapy, independent from CRS/ICANS, with macrophage-activation/HLH features and new or worsening cytopenias, hyperferritinemia, coagulopathy with hypofibrinogenemia and/or transaminitis. It typically emerges as CRS is resolving/resolved or with a new inflammatory worsening.

A substantially elevated or rapidly rising ferritin is required for identification, but ASTCT deliberately avoided one numeric cutoff. Look for transaminases over five times ULN, fibrinogen below 150 mg/dL or LLN, cytopenias, fever, LDH elevation, direct hyperbilirubinemia, coagulopathy, splenomegaly, hypoxia, renal/neurotoxicity and/or tissue hemophagocytosis. None of those additional findings alone is specific, and hemophagocytosis is not required. Exclude infection, malignancy progression, CRS recurrence, medications, liver injury and inherited/acquired HLH mimics.

Treatment intensity follows severity and the center pathway. Anakinra with or without corticosteroids is commonly considered early; dose/route/frequency are individualized. Ruxolitinib, emapalumab, etoposide or other rescue approaches require specialist judgment and evidence review. Emapalumab's FDA indication is refractory/recurrent/progressive or intolerant primary HLH—not blanket approval for secondary IEC-HS.

2. Early, Prolonged and Late Cytopenias

Cytopenias may occur early after lymphodepletion, persist beyond day +30, or recur after an initial recovery. Incidence and timing vary markedly by product and population; a biphasic pattern is possible but not required. Assess baseline marrow reserve and prior therapy, product/lymphodepletion, CRS/IEC-HS, infection, nutritional deficiency, immune destruction, medication toxicity, relapse and therapy-related myeloid/T-cell malignancy. Marrow examination, disease/MRD studies, infection testing and immune/nutritional labs are selected from the pattern.

Use transfusion and infection support while treating causes. G-CSF timing follows the product and center protocol; many programs avoid it during active CRS, but there is no universal day-14 prohibition. TPO-receptor agonists or a previously stored autologous stem-cell boost may help selected refractory cases after marrow/cause assessment; neither is an automatic platelet or day-based intervention.

3. Long-Term B-Cell Aplasia & Immunoglobulin Replacement

Assessment and replacement framework

• Trend immunoglobulins, B-cell recovery when clinically useful, infection history, antimicrobial needs, and vaccine timing.
• Hypogammaglobulinemia is expected after some B-cell-directed therapies but does not mandate identical replacement for every adult.
• Consider IVIG/SCIG for recurrent or serious infection with low IgG, profound deficiency, pediatric risk, or other protocol-defined indications. Dose and trough goals are patient- and program-specific.
• Reassess ongoing need as endogenous B-cell and immunoglobulin production recover.

Clinical Management Pearls

• B-cell aplasia can persist while functional CD19-directed CAR T cells remain, but duration varies. Monitor IgG, infections, and B-cell recovery at the interval specified by the product and survivorship plan, and reassess long-term need.
• For IVIG/SCIG, use the prescribed product's premedication, rate, and monitoring plan; routine premedication is not necessary for every patient and product.

---

4. Infection Prevention and Immunization

Select HSV/VZV, PJP, bacterial and antifungal prophylaxis from product, counts, CD4/B-cell recovery, corticosteroids/other immunosuppression, prior infection, geography and center guidance. TMP-SMX is preferred for PJP when tolerated; alternatives require G6PD, absorption and breakthrough-risk review. Antiviral and PJP stop dates are not determined from elapsed months alone. IVIG/SCIG is immune replacement for selected patients, not antibacterial prophylaxis on a universal trough schedule.

Coordinate revaccination with the cellular-therapy/infectious-disease plan, prior HCT, immune recovery, immunoglobulin replacement and immunosuppression. Inactivated vaccines may restart when a useful response is expected; live vaccines require the applicable national immune-competence gate.

5. Response, Treatment Failure, Relapse, and Follow-up

Treatment failure includes failure to manufacture or infuse a usable product, no objective response, early progression, or loss of a prior response. It is not interchangeable with CRS severity or B-cell recovery. Evaluate disease-specific symptoms, examination, blood counts, marrow or imaging response, MRD when validated, product expansion/persistence when clinically available, and mechanisms such as antigen loss. New cytopenias can reflect infection, immune toxicity, marrow suppression, relapse, or a subsequent myeloid or T-cell malignancy and require diagnostic workup rather than reflex growth factor alone.

Management is disease- and product-specific and may include salvage systemic therapy, another cellular product, bispecific therapy, radiation, HCT, a clinical trial, symptom-directed care, or goals-of-care transition. Nurses coordinate milestone visits, urgent symptom access, infection prevention, medication reconciliation, psychosocial/financial navigation, and transfer of the survivorship plan to local clinicians.

6. Product-Specific Delayed Warnings, Post-REMS Regulation and Survivorship

Immune Effector Cell-Associated Enterocolitis

In October 2025, FDA added a boxed warning for immune effector cell-associated enterocolitis to ciltacabtagene autoleucel (Carvykti). It may begin weeks to months after treatment with severe or prolonged diarrhea, abdominal pain, weight loss and malnutrition; complications can require parenteral nutrition and can be fatal. Promptly evaluate stool/infectious causes, fluid and nutritional status, and involve the cellular-therapy, gastroenterology and infectious-disease teams. Refractory cases also require evaluation for a gastrointestinal T-cell malignancy under the current label; this warning is product-specific, not a diagnosis for every CAR T recipient.

The June 2025 Elimination of CAR-T REMS - and What Replaced It

On June 27, 2025, the FDA eliminated the Risk Evaluation and Mitigation Strategies (REMS) programs for every approved BCMA- and CD19-directed autologous CAR T-cell immunotherapy, concluding that product labeling communicates the safety information adequately. This is one of the highest-yield "what changed" facts in modern cellular therapy nursing, and older review books still teach the retired rules.

Nursing translation. The regulatory scaffolding loosened; the clinical vigilance did not. Current labeling still directs the team to monitor patients at least daily for 7 days after infusion for CRS and neurologic toxicity, and to monitor for these toxicities for 2 weeks post-infusion. Many programs voluntarily retain longer caregiver and proximity expectations than the 2-week label minimum, so teach the patient the institutional plan while knowing the regulatory floor.

Surveillance for Secondary Malignancies

• In late 2023, the FDA issued safety communications regarding rare occurrences of secondary T-cell malignancies, including CAR-positive T-cell lymphomas and therapy-related myelodysplastic syndrome (t-MDS) / acute myeloid leukemia (t-AML).
• Long-term follow-up and reporting: FDA expects long-term observational follow-up for recipients of gene-modified cellular products, commonly extending to 15 years through manufacturer, registry, trial, or institutional mechanisms. Do not assume every patient is automatically enrolled in one CIBMTR pathway. Report a suspected subsequent malignancy promptly through the treating program and current FDA/manufacturer processes, and obtain tissue/pathology evaluation when feasible.